Alabama Medical Cannabis Market Analysis: A Program Built to Underperform

Alabama legalized medical cannabis in 2021. Litigation over the licensing process delayed actual sales for five years — the state's first dispensary, Callie's Apothecary in Montgomery, opened June 3-4, 2026. A second location opened in Talladega on August 28. The program allows no flower, no smoking, and no consumer vape cartridges — only tablets, capsules, tinctures, transdermal patches, suppositories, topical gels, lozenges, a specific gelatin cube product, and a narrow pharmaceutical-style inhalation category (nebulizers and inhaler oils). Pricing at Callie's runs roughly double the per-package shelf price of common 100mg gummy packs at an established operator in Florida. Against a modeled $1.4 billion full market and a $348 million mature-medical ceiling, this analysis expects Alabama to capture roughly 1% of potential revenue and 0.5% of potential volume once its remaining licensed competitors are operational — a 2027 estimate, not a 2026 one, since the program has no realistic path to that run rate on two open doors and a few months of sales. That's about $14 million a year — a fraction of MJBiz's own $270 million first-year projection, itself already a sharp revision upward from what MJBiz projected in 2022, even as the real program remained just as restrictive and suffered years of additional delay.

Market Overview

Senate Bill 46, the Compassion Act, passed the Alabama legislature in 2021. The Alabama Medical Cannabis Commission (AMCC) approved licensing rules in August 2022 and made three separate attempts to award business licenses: an initial round in June 2023 was stayed within days over scoring-tabulation concerns; a second round that August excluded Verano despite it remaining the highest-scoring integrated applicant even after rescoring, and Verano's subsequent suit was dismissed that October, but the round itself was undone after several other companies alleged the AMCC had violated the state's open meetings law. A third round followed in December 2023, but the dispensary licenses actually in use weren't approved until December 11, 2025 and issued January 8, 2026 — two more years beyond the third round. A separate lawsuit from five parents over access delays was dismissed in August 2025. In the integrated-facility litigation, a February 2026 appellate ruling then held that the circuit court had lacked jurisdiction to enjoin AMCC's December 2023 licensing decisions in the first place, voiding a lower court order from the year before and finding related challenges premature since the commission's own investigative-hearing process hadn't concluded — though the fourth dispensary license remains stayed and the entire Integrated Facility category is still in administrative proceedings. Callie's Apothecary made Alabama's first legal sale on June 3, 2026, with an official opening the next day.

Alabama's product list is the most restrictive in this series. State rules permit tablets, capsules, tinctures, transdermal patches, suppositories, topical gels, lozenges, a non-sugar-coated gelatinous cube product, and nebulizers or inhaler oils — a category that doesn't appear in Callie's current offering. Raw plant material, anything smokable or vapeable, and conventional edibles (cookies, candies, gummies made the ordinary way) are all explicitly prohibited. Callie's own menu, in practice, is just tablets, tinctures, topicals, and the gel cube. A patient's initial recommended dosage is capped at 50mg of THC per day; a physician can raise that to 75mg after 90 days if the lower dose isn't working, and if a terminal patient's recommended dose exceeds 75mg, the physician must notify them that their driver's license will be suspended as a result.

Licensing Structure

Two separate license tracks exist. Dispensary-only licenses are capped at four companies, each permitted up to three retail sites, for a 12-site ceiling; three companies (CCS of Alabama/Callie's, GP6 Wellness, RJK Holdings) currently hold licenses, with a fourth awarded to Yellowhammer Medical Dispensaries but still stayed pending litigation. Separately, the AMCC may issue up to five Integrated Facility licenses, each permitted up to five dispensing sites — a further 25-site ceiling — but that category is still in administrative hearings and has not resolved. Cultivator licenses are capped at 12 statewide; the commission chair confirmed nine cultivator, four processor, and four transporter licenses issued as of December 11, 2025. Combined, full deployment of the initial statutory license structure allows up to 37 dispensing sites — 12 under dispensary licenses and 25 under integrated-facility licenses — with additional sites possible later if patient demand warrants, though only 2 are open today.

Current State

As of the June 11, 2026 commission meeting, 481 patients had applied for a medical cannabis card and 446 had been issued one — a figure that's grown substantially since, given more than 800 patients had been served at Montgomery alone by late August. Over roughly the first eight calendar days of sales (about six operating days, since both locations run Monday–Friday), including the June 3 soft opening, Callie's Apothecary served 102 patients across 111 transactions, generating about $14,600 in pre-tax sales at an average ticket of $131.56 — a pace that annualizes to somewhere between $635,000 and $666,000 a year depending on which day-count basis is used, either way a small fraction of the $348 million mature-medical ceiling. The dispensary rationed purchases that first week due to limited supply, lifted by June 11, which cuts against reading the number as a clean baseline in either direction. By August 27–28, when the second dispensary opened in Talladega, the Montgomery location alone had served over 800 patients across more than 1,300 transactions — roughly an 8x increase in patients over about 11 weeks, though no updated dollar total was reported alongside it. As of that same June 11 meeting, 52 physicians were certified by the Alabama Board of Medical Examiners, but only 39 had completed the separate AMCC registration required to actually recommend cannabis, and just 21 had made a recommendation to a patient — a sharper supply-side constraint than the headline certification count. Products at Callie's ran $42–52 each as of that June 11 snapshot; a comparable gummy pack from an established Florida operator ran roughly $20–25 at regular shelf price around the same time, lower still on promotion — a per-pack, not per-mg, comparison, since Alabama's gel cube is separately dose-capped. Three more locations were targeted to open in September, though as of publication none had confirmed an opening date: GP6 Wellness's first two BamaBloom stores in Athens and Birmingham, and Callie's third location (after Montgomery and Talladega) in Bessemer.

Total Addressable Market

Alabama's population is approximately 5.19 million (Census, 2025), with roughly 22% under 18 per Census QuickFacts. Netting that and an estimated 18–20 cohort yields roughly 3.85 million adults 21 and over — this framework's standard age basis for cross-state consistency, though Alabama's own patient eligibility floor is actually lower: patients must be at least 19, or younger with a parent or legal guardian serving as registered caregiver, so the state's real addressable patient pool extends below this TAM's adult base. At 18% participation and 1.0 g/day, full capture of modeled demand comes to a ~$1.4 billion adult-use-equivalent ceiling at $5.50/g.

A defensible medical-only ceiling: assume a mature medical market converts about a quarter of that 18% pool into actual registered, purchasing patients — roughly 173,000 patients, spending at this framework's standard $2,008/year rate. That puts the mature medical ceiling at ~$348 million. Even the more current figure of 800-plus patients served is a fraction of a percent of the way there.

The Forecast

The structural inputs behind this underperformance forecast are already observable, even if the exact size of the shortfall is this analysis's own inference: a product catalog effectively excluding both flower and consumer vape cartridges — the two largest categories in most other markets — restricted edibles, a per-unit price running roughly double a mature market's, a population base less than half Georgia's and roughly one-sixth Texas's, and a five-year rollout delay that's left the state with two open dispensaries, 446 cards issued as of June 11, and just over 800 patients served at the original location three months in. The one product category with real pull — the gel cubes, Alabama's closest thing to an edible — gives the program some consumer appeal, but it isn't enough to offset the rest.

This analysis puts Alabama's legal capture at roughly 1% of the modeled $1.4 billion ceiling — call it $14 million a year — with volume capture running lower still, at 0.5%, reflecting that Alabama's elevated pricing lets it capture more dollars than product actually moved would otherwise suggest. That figure is a 2027 estimate, assuming the remaining licensed dispensaries and integrated facilities are operational by then; nothing about the current two-store, few-months-old rollout puts it in reach for 2026 itself. Both figures sit below every other state in this series to date, including Iowa's ~1.8%. Flower and vapor pens are the two largest product categories in essentially every state this publication has tracked; Iowa allows vaporizable forms, giving it a foothold in the larger of the two non-flower categories, while Alabama has none of the top formats in conventional form. That gap is a defensible reason to expect Alabama to underperform Iowa, not just match it. It also isn't offset by edibles' general popularity elsewhere: flower typically anchors legal-market demand, with vapes and edibles capturing important secondary shares once a market matures — Alabama is attempting to build one without either of the two dominant national categories, against a hemp market that already sells its own intoxicating hemp-THC edibles.

Across every state this publication has tracked category mix for, the formats Alabama's program is actually built around — capsules, tinctures, topicals — run to a low single-digit share of sales at most, often less, in markets where flower and vapes are also on the shelf. Alabama's version of those categories carries a real price premium and none of the competing formats to draw volume away from them, so that isn't a hard ceiling; it's closer to a floor-level sanity check on what demand these formats generate elsewhere. This analysis's 1% revenue-capture estimate sitting in that same low-single-digit range, despite Alabama's added frictions, is the direction the number should land in.

Worth contrasting against MJBiz's own public projections, which have moved sharply upward even as the real program remained just as restrictive and suffered years of additional delay. MJBizDaily's 2022 coverage projected $80–90 million in first-year Alabama sales, rising to $450–545 million by year four. Its 2026 reporting instead cites a newer MJBizFactbook projection of $270 million in Alabama's first year of operation — a separate, later estimate, not the same forecast continuing. That $270 million would imply roughly 19% capture of the modeled $1.4 billion ceiling in year one alone — performance in the range of an established medical market like Pennsylvania or Arkansas, not a program with no flower, no consumer vapes, and two open doors.

The Bottom Line

Alabama built a medical cannabis program with no flower, no consumer vapes, no conventional edibles, prices roughly double a mature market's, and a population and rollout timeline that limit it further still. Against a modeled $1.4 billion ceiling, this analysis expects Alabama to land at the bottom of this series on both revenue and volume capture — a structurally narrow program serving a structurally narrow slice of the patients it was built for.

This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.